ReviewClinical microbiology reviews2019
Tick-Borne Flaviviruses, with a Focus on Powassan Virus.
Review in Clinical microbiology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Trends and Opportunities in Tick-Borne Disease Geography.Journal of medical entomology · 2021Pooled it
- Pathogenesis and neurotropism of a contemporary Powassan virus lineage II strain in mice.Journal of virology · 2026Article
- Powassan Virus NS5 Antagonizes TYK2-Mediated Immune Signaling Pathways.bioRxiv : the preprint server for biology · 2026Article
- Powassan Virus Infects Mouse Testes and Reveals a Protective Role for Phagocytic Cells.Viruses · 2026Article
- Tick-borne viruses: discovery, clinical aspects, influencing factors and control.Nature reviews. Microbiology · 2026Review
- Powassan Virus in the United States: An AI-Integrative One Health Scoping Review of Ecological Drivers, Zoonotic Interactions, Symptom Profiles, and Public Health Implications.Infectious disease reports · 2026Review
- Article
- Article
- Powassan Virus Seroprevalence in a U.S. Servicemember Population at High Risk for Tick Exposure.medRxiv : the preprint server for health sciences · 2026Article
- Type I and III interferon responses restrict infection by tick-borne orthoflaviviruses through IFI6.Journal of virology · 2026Article
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Powassan virus.Trends in microbiology · 2026Article
- Fulminant Powassan Virus Encephalitis Presenting as Acute Ischemic Stroke: A Case Report.Journal of Brown hospital medicine · 2026Article
- Characterization of virus neuroinvasion, blood-brain barrier integrity and neuroinflammation following Powassan virus infection in mice.Frontiers in immunology · 2026Article
- Article
- Pathogenicity and virulence of Powassan virus.Virulence · 2025Review
- Review
- Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control.Vaccines · 2025Review
- Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus.Science advances · 2025Article
- Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tick-borne pathogen Powassan virus is a rare cause of encephalitis in North America and the Russian Far East. The number of documented cases described since the discovery of Powassan virus in 1958 may be <150, although detection of cases has increased over the past decade. In the United States, the incidence of Powassan virus infections expanded from the estimated 1 case per year prior to 2005 to 10 cases per year during the subsequent decade. The increased detection rate may be associated with several factors, including enhanced surveillance, the availability of improved laboratory diagnostic methods, the expansion of the vector population, and, perhaps, altered human activities that lead to more exposure. Nonetheless, it remains unclear whether Powassan virus is indeed an emerging threat or if enzootic cycles in nature remain more-or-less stable with periodic fluctuations of host and vector population sizes. Despite the low disease incidence, the approximately 10% to 15% case fatality rate of neuroinvasive Powassan virus infection and the temporary or prolonged sequelae in >50% of survivors make Powassan virus a medical concern requiring the attention of public health authorities and clinicians. The medical importance of Powassan virus justifies more research on developing specific and effective treatments and prevention and control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.